Ferrer Internacional

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents specifically designed to combat multidrug-resistant (MDR) Gram-negative infections. Founded in 2014, the company employs its innovative drug discovery platform, PasNas, to identify pathogen-specific antibacterial properties of various molecules. This platform not only promotes compounds effective against MDR strains but also emphasizes the importance of incorporating favorable pharmacokinetic and toxicological characteristics early in the development process. By focusing on first-in-class drugs and leveraging new mechanisms of action, ABAC Therapeutics aims to provide scalable and effective therapeutic alternatives for patients afflicted by antibiotic-resistant bacterial pathogens, addressing a critical need in modern medicine. As of November 2019, ABAC Therapeutics operates as a subsidiary of Tibidabo Ventures.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

Venter Pharma SL is a biotechnology company based in Alcobendas, Spain, dedicated to developing diagnostic drugs for lactose intolerance and other digestive disorders. Founded in 2003, the company emerged from research conducted by PhD Juan José Aragón Reyes and Alfonso Fernández Mayoralas at the Autonomous University of Madrid and the Spanish National Research Council. Venter Pharma focuses on creating innovative solutions that simplify and enhance clinical diagnosis, particularly in gastroenterology. Its flagship product, LacTEST, is designed to assist healthcare professionals in diagnosing lactose intolerance using a novel active substance called Gaxilose. By addressing common digestive pathologies, Venter Pharma aims to improve patient outcomes and facilitate more effective treatments for conditions with high prevalence, such as lactose intolerance and inflammatory diseases.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.